Impact of Baseline Body Mass Index on Immunotherapy Outcomes in Patients With Non-small-cell Lung Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F25%3AW0000007" target="_blank" >RIV/00064211:_____/25:W0000007 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10505788 RIV/00216208:11120/25:43929134 RIV/00216208:11140/25:10505788

Výsledek na webu

<a href="https://dx.doi.org/10.21873/anticanres.17892" target="_blank" >https://dx.doi.org/10.21873/anticanres.17892</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.17892" target="_blank" >10.21873/anticanres.17892</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of Baseline Body Mass Index on Immunotherapy Outcomes in Patients With Non-small-cell Lung Cancer

Popis výsledku v původním jazyce

Background/Aim: Assessment of nutritional status plays an important role in treatment of patients with lung cancer. We conducted a real-world study to investigate the potential prognostic value of baseline body mass index (BMI) in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Patients and Methods: We retrospectively analysed data from 154 patients with advanced NSCLC treated with ICIs in the first or second line. Patients were stratified into two groups: BMI <25 kg/m(2) and BMI >= 25 kg/m(2). We investigated the impact of BMI on overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), and objective response rate (ORR) across the overall population and within prespecified subgroups defined by BMI. Results: Patients with BMI >= 25 kg/m(2) (n=88) had a significantly better ORR compared to those with BMI <25 kg/m(2)(n=66): 78.4% vs. 62.1%, p=0.03. There was no significant improvement in PFS, TTF or OS in the overall population. Subgroup analyses showed significant improvement in OS in favour of the BMI >= 25 kg/m(2) group in non-smokers, in the subgroup receiving first-line immunotherapy, and in the subgroup with high expression of programmed cell death ligand 1. There was significant improvement in ORR in favour of the BMI >= 25 kg/m(2) group in several subgroups. No significant improvements in PFS and TTF in subgroup analyses were observed. Conclusion: Our real-world study suggests that BMI might potentially act as a predictor for ORR in patients with advanced NSCLC treated with ICIs and should be considered in treatment decision-making. Additionally, we also observed a positive trend in OS among this group of patients.

Název v anglickém jazyce

Impact of Baseline Body Mass Index on Immunotherapy Outcomes in Patients With Non-small-cell Lung Cancer

Popis výsledku anglicky

Background/Aim: Assessment of nutritional status plays an important role in treatment of patients with lung cancer. We conducted a real-world study to investigate the potential prognostic value of baseline body mass index (BMI) in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Patients and Methods: We retrospectively analysed data from 154 patients with advanced NSCLC treated with ICIs in the first or second line. Patients were stratified into two groups: BMI <25 kg/m(2) and BMI >= 25 kg/m(2). We investigated the impact of BMI on overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), and objective response rate (ORR) across the overall population and within prespecified subgroups defined by BMI. Results: Patients with BMI >= 25 kg/m(2) (n=88) had a significantly better ORR compared to those with BMI <25 kg/m(2)(n=66): 78.4% vs. 62.1%, p=0.03. There was no significant improvement in PFS, TTF or OS in the overall population. Subgroup analyses showed significant improvement in OS in favour of the BMI >= 25 kg/m(2) group in non-smokers, in the subgroup receiving first-line immunotherapy, and in the subgroup with high expression of programmed cell death ligand 1. There was significant improvement in ORR in favour of the BMI >= 25 kg/m(2) group in several subgroups. No significant improvements in PFS and TTF in subgroup analyses were observed. Conclusion: Our real-world study suggests that BMI might potentially act as a predictor for ORR in patients with advanced NSCLC treated with ICIs and should be considered in treatment decision-making. Additionally, we also observed a positive trend in OS among this group of patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ANTICANCER RESEARCH

ISSN

0250-7005

e-ISSN

1791-7530

Svazek periodika

45

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

8

Strana od-do

5579-5586

Kód UT WoS článku

001676259800001

EID výsledku v databázi Scopus

—